Hologic (NASDAQ:HOLX) had its price objective hoisted by equities research analysts at Morgan Stanley from $53.00 to $55.00 in a research report issued to clients and investors on Tuesday, BenzingaRatingsTable reports. The firm presently has an “equal weight” rating on the medical equipment provider’s stock. Morgan Stanley’s price target suggests a potential upside of 9.08% from the company’s current price.
A number of other research analysts also recently issued reports on HOLX. Zacks Investment Research downgraded shares of Hologic from a “hold” rating to a “sell” rating and set a $52.00 price objective on the stock. in a research report on Tuesday, April 28th. BidaskClub downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, May 27th. Needham & Company LLC started coverage on shares of Hologic in a research report on Tuesday, June 2nd. They set a “buy” rating and a $60.00 target price on the stock. JPMorgan Chase & Co. boosted their target price on shares of Hologic from $45.00 to $55.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Finally, Stifel Nicolaus dropped their target price on shares of Hologic from $52.00 to $45.00 and set a “hold” rating on the stock in a research report on Wednesday, April 8th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and eleven have issued a buy rating to the stock. Hologic has an average rating of “Hold” and an average target price of $56.06.
Shares of Hologic stock traded down $1.59 on Tuesday, reaching $50.42. The stock had a trading volume of 59,628 shares, compared to its average volume of 2,760,014. The company has a 50 day moving average price of $50.90 and a 200 day moving average price of $48.72. The company has a quick ratio of 1.04, a current ratio of 1.31 and a debt-to-equity ratio of 1.32. Hologic has a 1 year low of $26.49 and a 1 year high of $55.25. The stock has a market capitalization of $13.71 billion, a P/E ratio of 22.71, a P/E/G ratio of 3.31 and a beta of 1.44.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, April 29th. The medical equipment provider reported $0.57 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.57. Hologic had a net margin of 18.53% and a return on equity of 30.49%. The firm had revenue of $756.10 million for the quarter, compared to the consensus estimate of $756.10 million. During the same quarter in the previous year, the firm earned $0.58 EPS. On average, analysts forecast that Hologic will post 2.25 earnings per share for the current fiscal year.
In related news, CEO Stephen P. Macmillan sold 190,996 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $50.97, for a total value of $9,735,066.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel John M. Griffin sold 4,906 shares of the business’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $50.00, for a total transaction of $245,300.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 238,345 shares of company stock valued at $12,185,194. Company insiders own 1.00% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of HOLX. First Trust Advisors LP lifted its stake in shares of Hologic by 100.1% in the 4th quarter. First Trust Advisors LP now owns 444,638 shares of the medical equipment provider’s stock valued at $23,215,000 after purchasing an additional 222,378 shares during the period. Cambridge Investment Research Advisors Inc. purchased a new stake in Hologic in the 4th quarter worth $229,000. Advisory Services Network LLC increased its holdings in Hologic by 36.7% in the 4th quarter. Advisory Services Network LLC now owns 2,773 shares of the medical equipment provider’s stock worth $145,000 after acquiring an additional 745 shares in the last quarter. US Bancorp DE increased its holdings in Hologic by 57.2% in the 4th quarter. US Bancorp DE now owns 17,278 shares of the medical equipment provider’s stock worth $902,000 after acquiring an additional 6,286 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in Hologic by 15.4% in the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 54,068 shares of the medical equipment provider’s stock worth $2,806,000 after acquiring an additional 7,233 shares in the last quarter. Hedge funds and other institutional investors own 92.45% of the company’s stock.
Hologic Company Profile
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.